MA33032B1 - Pyrimidines condensees - Google Patents
Pyrimidines condenseesInfo
- Publication number
- MA33032B1 MA33032B1 MA34073A MA34073A MA33032B1 MA 33032 B1 MA33032 B1 MA 33032B1 MA 34073 A MA34073 A MA 34073A MA 34073 A MA34073 A MA 34073A MA 33032 B1 MA33032 B1 MA 33032B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- primidines
- intensive
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La présente invention concerne des composés de formule (I) ou un N-oxyde, un sel, un tautomère ou un stéréo-isomère desdits composés, ou un sel dudit N-oxyde, tautomère ou stéréo-isomère desdits composés, où le cycle B et la pyrimidine avec laquelle il est condensé, R4, R5, R6, R7, m et n ont les significations telles que données dans la description et les revendications, qui sont des inhibiteurs efficaces de la voie Pi3K/Akt, des procédés pour leur production et leur utilisation en tant qu'agents pharmaceutiques.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075072 | 2009-02-13 | ||
EP09152914 | 2009-02-16 | ||
PCT/EP2010/000620 WO2010091808A1 (fr) | 2009-02-13 | 2010-02-02 | Pyrimidines condensées |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33032B1 true MA33032B1 (fr) | 2012-02-01 |
Family
ID=42115325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34073A MA33032B1 (fr) | 2009-02-13 | 2010-02-02 | Pyrimidines condensees |
Country Status (29)
Country | Link |
---|---|
US (1) | US8957064B2 (fr) |
EP (1) | EP2396330B1 (fr) |
JP (1) | JP5777526B2 (fr) |
KR (1) | KR20110114663A (fr) |
CN (1) | CN102317291B (fr) |
AR (1) | AR075253A1 (fr) |
AU (1) | AU2010213192A1 (fr) |
BR (1) | BRPI1008782A2 (fr) |
CA (1) | CA2752105C (fr) |
CL (1) | CL2011001972A1 (fr) |
CO (1) | CO6410298A2 (fr) |
CR (1) | CR20110432A (fr) |
CU (1) | CU20110159A7 (fr) |
DO (1) | DOP2011000260A (fr) |
EA (1) | EA201101186A1 (fr) |
EC (1) | ECSP11011258A (fr) |
ES (1) | ES2580779T3 (fr) |
HK (1) | HK1165423A1 (fr) |
IL (1) | IL213953A0 (fr) |
MA (1) | MA33032B1 (fr) |
MX (1) | MX2011008583A (fr) |
PE (1) | PE20120534A1 (fr) |
SG (1) | SG172898A1 (fr) |
SV (1) | SV2011003997A (fr) |
TN (1) | TN2011000404A1 (fr) |
TW (1) | TW201036978A (fr) |
UY (1) | UY32432A (fr) |
WO (1) | WO2010091808A1 (fr) |
ZA (1) | ZA201106663B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010001746A (es) * | 2007-08-14 | 2010-03-10 | Bayer Schering Pharma Ag | Pirimidinas biciclicas fusionadas. |
CA2806655A1 (fr) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Imidazo[1,2-b]pyridazines substituees |
US8987286B2 (en) * | 2010-12-16 | 2015-03-24 | Bayer Intellectual Property Gmbh | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway |
EA024890B1 (ru) * | 2011-04-07 | 2016-10-31 | Байер Интеллектчуал Проперти Гмбх | Имидазопиридазины в качестве ингибиторов akt киназы |
JP6077642B2 (ja) | 2012-04-10 | 2017-02-08 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用 |
MX361136B (es) | 2013-01-23 | 2018-11-28 | Astrazeneca Ab | Compuestos quimicos. |
JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
JP6139789B2 (ja) | 2013-10-16 | 2017-05-31 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 |
EA037361B1 (ru) * | 2016-06-16 | 2021-03-18 | Янссен Фармацевтика Нв | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета |
EP3548035A4 (fr) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations |
US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
WO2018175906A1 (fr) | 2017-03-24 | 2018-09-27 | Nanosyn, Inc. | Composés de triazolo-pyrimidine fusionnés ayant une application pharmaceutique utile |
JP7053654B2 (ja) | 2017-03-29 | 2022-04-12 | ヤンセン ファーマシューティカ エヌ.ベー. | PI3Kβ阻害剤としてのキノキサリン及びピリドピラジン誘導体 |
WO2020159942A1 (fr) * | 2019-01-29 | 2020-08-06 | Tosk, Inc. | Modulateurs de pyrazolopyrimidine de ras gtpase |
WO2020227491A1 (fr) * | 2019-05-07 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Triazolopyrimidines deutérés |
CN112921405B (zh) * | 2019-12-05 | 2023-06-27 | 成都先导药物开发股份有限公司 | 一种合成On-DNA吡唑并[1,5-a]嘧啶化合物的方法 |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种***并嘧啶类化合物及其制备方法和应用 |
CN114874221A (zh) * | 2022-05-12 | 2022-08-09 | 广州佳途科技股份有限公司 | 一种rip2激酶抑制剂中间体及其合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1541615A (en) * | 1975-06-26 | 1979-03-07 | Philip Morris Inc | Azetidine compounds and process for their production |
GB1543308A (en) | 1975-06-26 | 1979-04-04 | Philip Morris Inc | Azetidine compounds and process for their production |
CN1085962C (zh) | 1996-06-25 | 2002-06-05 | W·L·戈尔有限公司 | 柔性防水防油复合材料 |
TW414846B (en) | 1997-11-05 | 2000-12-11 | Mitsubishi Heavy Ind Ltd | Combustion apparatus |
GB9821898D0 (en) | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
US7399764B2 (en) * | 2002-10-30 | 2008-07-15 | Merck & Co., Inc. | Inhibitors of Akt activity |
EP1622616B1 (fr) | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activite akt |
AU2004233827B2 (en) * | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
ATE499364T1 (de) | 2004-04-09 | 2011-03-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
CN1942463A (zh) | 2004-04-15 | 2007-04-04 | 安斯泰来制药株式会社 | 2-氨基嘧啶衍生物 |
BRPI0511571A (pt) * | 2004-05-27 | 2008-01-02 | Pfizer | derivados de aminopiridina como agonistas de dopamina d3 seletivos |
US7544677B2 (en) | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
EP1827436A4 (fr) | 2004-12-15 | 2011-08-10 | Merck Sharp & Dohme | Inhibiteurs d'activite akt |
CA2597456A1 (fr) | 2005-02-14 | 2006-08-31 | Merck & Co., Inc. | Inhibiteurs d'activite d'akt |
NZ563423A (en) | 2005-06-10 | 2010-05-28 | Merck Sharp & Dohme | Inhibitors of AKT activity |
EP1942900B1 (fr) | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Utilisation de derives de pyrazolo [1,5-a] pyrimidine comme inhibiteurs de proteines kinases procedes d'inhibition de proteines kinases |
ATE533770T1 (de) * | 2005-10-06 | 2011-12-15 | Schering Corp | Pyrazolopyrimidine als proteinkinaseinhibitoren |
EP2086965B1 (fr) | 2006-11-02 | 2010-02-10 | Vertex Pharmaceuticals, Inc. | Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de protéines kinases |
JP5572388B2 (ja) * | 2006-11-22 | 2014-08-13 | インサイト・コーポレイション | キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン |
MX2010001746A (es) | 2007-08-14 | 2010-03-10 | Bayer Schering Pharma Ag | Pirimidinas biciclicas fusionadas. |
-
2010
- 2010-02-02 US US13/201,277 patent/US8957064B2/en not_active Expired - Fee Related
- 2010-02-02 JP JP2011549468A patent/JP5777526B2/ja not_active Expired - Fee Related
- 2010-02-02 KR KR1020117018840A patent/KR20110114663A/ko not_active Application Discontinuation
- 2010-02-02 SG SG2011049582A patent/SG172898A1/en unknown
- 2010-02-02 EP EP10703014.0A patent/EP2396330B1/fr not_active Not-in-force
- 2010-02-02 CN CN201080007743.1A patent/CN102317291B/zh not_active Expired - Fee Related
- 2010-02-02 PE PE2011001485A patent/PE20120534A1/es not_active Application Discontinuation
- 2010-02-02 EA EA201101186A patent/EA201101186A1/ru unknown
- 2010-02-02 WO PCT/EP2010/000620 patent/WO2010091808A1/fr active Application Filing
- 2010-02-02 AU AU2010213192A patent/AU2010213192A1/en not_active Abandoned
- 2010-02-02 ES ES10703014.0T patent/ES2580779T3/es active Active
- 2010-02-02 CA CA2752105A patent/CA2752105C/fr not_active Expired - Fee Related
- 2010-02-02 MX MX2011008583A patent/MX2011008583A/es unknown
- 2010-02-02 MA MA34073A patent/MA33032B1/fr unknown
- 2010-02-02 BR BRPI1008782A patent/BRPI1008782A2/pt not_active IP Right Cessation
- 2010-02-10 UY UY0001032432A patent/UY32432A/es not_active Application Discontinuation
- 2010-02-12 AR ARP100100406A patent/AR075253A1/es unknown
- 2010-02-12 TW TW099104834A patent/TW201036978A/zh unknown
-
2011
- 2011-07-06 IL IL213953A patent/IL213953A0/en unknown
- 2011-08-10 TN TN2011000404A patent/TN2011000404A1/fr unknown
- 2011-08-11 EC EC2011011258A patent/ECSP11011258A/es unknown
- 2011-08-12 CU CU20110159A patent/CU20110159A7/es unknown
- 2011-08-12 SV SV2011003997A patent/SV2011003997A/es unknown
- 2011-08-12 DO DO2011000260A patent/DOP2011000260A/es unknown
- 2011-08-12 CR CR20110432A patent/CR20110432A/es unknown
- 2011-08-12 CL CL2011001972A patent/CL2011001972A1/es unknown
- 2011-08-12 CO CO11103122A patent/CO6410298A2/es not_active Application Discontinuation
- 2011-09-12 ZA ZA2011/06663A patent/ZA201106663B/en unknown
-
2012
- 2012-06-27 HK HK12106259.9A patent/HK1165423A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33032B1 (fr) | Pyrimidines condensees | |
MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
MA31608B1 (fr) | Pyrimidines bicycliques condensees | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
MA31419B1 (fr) | Derives de pyridine | |
MA33240B1 (fr) | Inhibiteurs de bêta-sécrétase | |
TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
MA31609B1 (fr) | Imidazoles fusionnes pour le traitement du cancer | |
MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
MA33492B1 (fr) | Inhibiteurs de bace | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA29688B1 (fr) | Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine | |
MA32965B1 (fr) | Derives de sulfonamides | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
MX2010009995A (es) | Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana. | |
MA38287B1 (fr) | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit |